Participated as a new investor in Obsidian Therapeutics' $350M private placement concurrent with its merger with Galera Therapeutics.
Obsidian Therapeutics is pioneering engineered TIL cell therapies using its proprietary cytoDRiVE® platform to improve outcomes for patients with solid tumor malignancies
Obsidian Therapeutics is pioneering engineered TIL cell therapies using its proprietary cytoDRiVE® platform to improve outcomes for patients with solid tumor malignancies.